{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:38:26Z","timestamp":1787017106251,"version":"build-2736575974"},"reference-count":54,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007820","name":"Alliance for Lupus Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2018,4,4]]},"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Activation of endosomal toll-like receptor (TLR)7 or TLR9 has been proposed as a critical step for the initiation and development of SLE. Traditional spontaneous lupus models normally introduce multiple risk alleles, thereby adding additional confounding factors. In the induced lupus models, the role of TLR9 remains unclear. In the present study, we explored the role of an imbalance between TLR7 and TLR9 pathways in the pathogenesis of lupus and its associated vasculopathy using the imiquimod model in TLR9 KO\/B6 background.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Wild type (WT) and Tlr9\n                      <jats:sup>-\/-<\/jats:sup>\n                      mice were epicutaneously treated with imiquimod cream 5% on both ears three times per week for indicated times. At euthanasia, mice were analysed for organ involvement, endothelium-dependent vasorelaxation, serum autoantibodies, and innate and adaptive immune responses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with the lupus-like phenotype that develops in imiquimod-treated WT mice, Tlr9\n                      <jats:sup>-\/-<\/jats:sup>\n                      mice exposed to imiquimod have increased severity of autoimmunity features and inflammatory phenotype that develops at earlier stages. These abnormalities are characterised by enhanced TLR7 expression and immune activation, increased immune complex deposition, Th1 T cells and dendritic cell kidney infiltration and significant impairments in endothelial function. Modulation of TLR7 expression was observed in the Tlr9\n                      <jats:sup>-\/-<\/jats:sup>\n                      mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings further underscore the protective role of TLR9 in TLR7-driven autoimmunity and also in the development of vasculopathy, further strengthening the importance of tightly manipulating TLRs in putative therapeutic strategies. This study provides a new model of accelerated lupus phenotype driven by danger-associated molecular patterns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2018-000259","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T11:51:28Z","timestamp":1527853888000},"page":"e000259","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Accelerated model of lupus autoimmunity and vasculopathy driven by toll-like receptor 7\/9 imbalance"],"prefix":"10.1136","volume":"5","author":[{"given":"Yudong","family":"Liu","sequence":"first","affiliation":[{"name":"Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickie L","family":"Seto","sequence":"additional","affiliation":[{"name":"Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carmona-Rivera","sequence":"additional","affiliation":[{"name":"Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana J","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"2025091511453897000_5.1.e000259.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359"},{"key":"2025091511453897000_5.1.e000259.2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/BOR.0000000000000307","article-title":"Update on cardiovascular disease in lupus","volume":"28","author":"Lewandowski","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2025091511453897000_5.1.e000259.3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052331"},{"key":"2025091511453897000_5.1.e000259.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.07.013"},{"key":"2025091511453897000_5.1.e000259.5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902592"},{"key":"2025091511453897000_5.1.e000259.6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050338"},{"key":"2025091511453897000_5.1.e000259.7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.2.1349"},{"key":"2025091511453897000_5.1.e000259.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.11.001"},{"key":"2025091511453897000_5.1.e000259.9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003340"},{"key":"2025091511453897000_5.1.e000259.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2012.02.006"},{"key":"2025091511453897000_5.1.e000259.11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501943"},{"key":"2025091511453897000_5.1.e000259.12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080462"},{"key":"2025091511453897000_5.1.e000259.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2010.05.004"},{"key":"2025091511453897000_5.1.e000259.14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/art.38298","article-title":"Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus","volume":"66","author":"Yokogawa","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025091511453897000_5.1.e000259.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.09.009"},{"key":"2025091511453897000_5.1.e000259.16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1124978"},{"key":"2025091511453897000_5.1.e000259.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3198"},{"key":"2025091511453897000_5.1.e000259.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089086"},{"key":"2025091511453897000_5.1.e000259.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205365"},{"key":"2025091511453897000_5.1.e000259.20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67390"},{"key":"2025091511453897000_5.1.e000259.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.34504"},{"key":"2025091511453897000_5.1.e000259.22","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309353773"},{"key":"2025091511453897000_5.1.e000259.23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500792"},{"key":"2025091511453897000_5.1.e000259.24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.5.2293"},{"key":"2025091511453897000_5.1.e000259.25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20122798"},{"key":"2025091511453897000_5.1.e000259.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2010.01.001"},{"key":"2025091511453897000_5.1.e000259.27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132620"},{"key":"2025091511453897000_5.1.e000259.28","doi-asserted-by":"publisher","DOI":"10.1038\/nri2358"},{"key":"2025091511453897000_5.1.e000259.29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202739"},{"key":"2025091511453897000_5.1.e000259.30","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.64"},{"key":"2025091511453897000_5.1.e000259.31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78087"},{"key":"2025091511453897000_5.1.e000259.32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ced.13174","article-title":"Imiquimod-induced cutaneous lupus erythematosus with antinuclear antibodies showing a homogenous pattern","volume":"42","author":"Jim\u00e9nez-Gallo","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"2025091511453897000_5.1.e000259.33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/DAD.0b013e3181f2bf9e","article-title":"Lupus erythematosus-like reaction in imiquimod-treated skin: a report of 2 cases","volume":"33","author":"Chan","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"2025091511453897000_5.1.e000259.34","first-page":"1022","article-title":"Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses","volume":"9","author":"Burnett","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"2025091511453897000_5.1.e000259.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173471","article-title":"Toll-like receptor 9 suppresses lupus disease in Fas-sufficient MRL Mice","volume":"12","author":"Nickerson","year":"2017","journal-title":"PLoS One"},{"key":"2025091511453897000_5.1.e000259.36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.159.2.629"},{"key":"2025091511453897000_5.1.e000259.37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202195"},{"key":"2025091511453897000_5.1.e000259.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1209372109"},{"key":"2025091511453897000_5.1.e000259.39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400098"},{"key":"2025091511453897000_5.1.e000259.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.05.010"},{"key":"2025091511453897000_5.1.e000259.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314121111"},{"key":"2025091511453897000_5.1.e000259.42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401720"},{"key":"2025091511453897000_5.1.e000259.43","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260732"},{"key":"2025091511453897000_5.1.e000259.44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.2.781"},{"key":"2025091511453897000_5.1.e000259.45","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.242"},{"key":"2025091511453897000_5.1.e000259.46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.7.3915"},{"key":"2025091511453897000_5.1.e000259.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.05.013"},{"key":"2025091511453897000_5.1.e000259.48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902199"},{"key":"2025091511453897000_5.1.e000259.49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001782"},{"key":"2025091511453897000_5.1.e000259.50","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.302407"},{"key":"2025091511453897000_5.1.e000259.51","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065961"},{"key":"2025091511453897000_5.1.e000259.52","first-page":"1708","article-title":"Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus","volume":"34","author":"Demirci","year":"2007","journal-title":"J Rheumatol"},{"key":"2025091511453897000_5.1.e000259.53","doi-asserted-by":"publisher","DOI":"10.1002\/art.21755"},{"key":"2025091511453897000_5.1.e000259.54","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket316"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2018-000259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T18:45:49Z","timestamp":1757961949000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2018-000259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,5,14]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/lupus-2018-000259"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2018-000259","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}